Efficacy and Safety of Xuebijing Injection Combined With Ulinastatin as Adjunctive Therapy on Sepsis: A Systematic Review and Meta-Analysis
Authors:
Open Access
- 24 July 2018
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 9, 743
Abstract
Background: Xuebijing injection (XBJ), transforming from Xuefuzhuyu decoction, is the only Chinese medicine injection approved for sepsis. XBJ and ulinastatin (UTI) combination therapy is supposed to be beneficial for sepsis patients. To fill the gap between the lack of evidence for the efficacy of combination therapy and its increasing application among patients, an extensive meta-analysis was performed. Methods: Eight databases were searched to identify randomized controlled trials (RCTs) comparing XBJ plus UTI with UTI alone in treating sepsis from inception to February 5, 2018. Data extraction and methodological quality assessment of the included RCTs were implemented by two investigators independently. All data were synthesized and analyzed utilizing Review Manager 5.3. Results: Seventeen RCTs with a total of 1,247 participants corresponded with the inclusion criteria of our study. The findings reflected that in comparison to single UTI, XBJ and UTI combination therapy could significantly lower 28-day mortality (RR = 0.54, 95% CI [0.39, 0.73], P < 0.0001), shorten duration of mechanical ventilation (SMD = −1.13, 95% CI [−1.30, −0.95], P < 0.00001), reduce length of ICU stay (SMD = −0.84, 95% CI [−1.00, −0.67], P < 0.00001), and decrease APACHE II score (SMD = −1.09, 95% CI [−1.49, −0.69], P < 0.00001). Additionally, XBJ plus UTI had superiority over single UTI in lowering PCT levels (SMD = −1.61, 95% CI [−2.23, −0.98], P < 0.00001), and improving inflammatory cytokines—IL-6 and TNF-α levels (SMD = −1.45, 95% CI [−1.71, −1.19], P < 0.00001; SMD = −1.11, 95% CI [−1.42, −0.80], P < 0.00001). Moreover, CRP, hs-CRP, and LPS levels were remarkably reduced by XBJ plus UTI compared with UTI alone (SMD = −1.50, 95% CI [−2.00, −1.00], P < 0.00001; SMD = −1.31, 95% CI [−1.70, −0.93], P < 0.00001; SMD = −1.17, 95% CI [−1.42, −0.92], P < 0.00001). Three studies involving 14 patients reported the occurrences of adverse events. Conclusions: Comparing with UTI alone, XBJ and UTI combination therapy appeared to be more effective for sepsis. However, owing to the limitations of this meta-analysis, additional RCTs with higher-quality and more rigorous design are needed to confirm our findings.Keywords
This publication has 33 references indexed in Scilit:
- Hospitalizations, costs, and outcomes of severe sepsis in the United States 2003 to 2007Critical Care Medicine, 2012
- The Cochrane Collaboration's tool for assessing risk of bias in randomised trialsBMJ, 2011
- Long-term Cognitive Impairment and Functional Disability Among Survivors of Severe SepsisJAMA, 2010
- The structural basis of lipopolysaccharide recognition by the TLR4–MD-2 complexNature, 2009
- Pathophysiology of SepsisThe American Journal of Pathology, 2007
- Evaluation of serum C-reactive protein, procalcitonin, tumor necrosis factor alpha, and interleukin-10 levels as diagnostic and prognostic parameters in patients with community-acquired sepsis, severe sepsis, and septic shockEuropean Journal of Clinical Microbiology & Infectious Diseases, 2006
- Measuring inconsistency in meta-analysesBMJ, 2003
- 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions ConferenceIntensive Care Medicine, 2003
- Pro‐ versus Anti‐inflammatory Cytokine Profile in Patients with Severe Sepsis: A Marker for Prognosis and Future Therapeutic OptionsThe Journal of Infectious Diseases, 2000
- Definitions for Sepsis and Organ Failure and Guidelines for the Use of Innovative Therapies in SepsisChest, 1992